24 / 37
Page 78
Notes:
conferenceseries
.com
Volume 9, Issue 9 (Suppl)
J Cancer Sci Ther, an open access journal
ISSN: 1948-5956
World Cancer 2017
October 19-21, 2017
25
th
WORLD CANCER CONFERENCE
October 19-21, 2017 | Rome, Italy
The impact of rerouting cancer diagnoses from emergency presentations to GP referrals: Evidence
from population-based patient-level data
Mauro Laudicella
1
, Brendan Walsh
2
, Elaine Burns
3
, Paolo Li Donni
4
and
Peter C Smith
5
1
City University London, UK
2
Economic and Social Research Institute, Ireland
3
Imperial College London- St Mary’s Campus, UK
4
University of Palermo, Italy
5
Imperial College Business School, UK
Background:
Studies on alternative routes to diagnosis stimulated successful policy interventions reducing the number of
emergency diagnoses. A dearth of evidence on costs might prevent new policies from achieving more ambitious targets.
Methods:
Retrospective cohort study on colorectal (88,051), breast (90,387), prostate (96,219), and lung (97,696) cancer patients
diagnosed after a GP referral or an emergency presentation (EP) in the English Cancer Registry. Costs of care and survival were
compared one year before and five years after diagnosis, including non-conversion costs. Basu-Manning estimator was used to
calculate the effect of rerouting patients after risk-adjusting.
Results:
The cost per year of life saved is £6,456 in colorectal, £1,057 in breast, -£662 in prostate (savings), and £819 in lung
cancer (three years only). Reducing the overall proportion of EP to those achieved by the 20% of CCGs with the lowest EP
percentage would result in £11,481,948 against 1,863 years of life saved for Colorectal, £847,750 against 889 years for breast,
-£943,434 (cost savings) against 1,195 years for prostate, and £609,938 against 1,011 years for lung cancer.
Conclusion:
Rerouting diagnoses from EP to GP/TWW referral appears an achievable target that can produce large benefits
to patients against modest additional costs to the NHS.
Biography
Mauro Laudicella is a Senior Lecturer in Health Economics in the School of Health Sciences at City University London and an Honorary Research Fellow in the
Business School at Imperial College London. He is currently leading a three-year research programme investigating the costs of cancer in England sponsored
by Macmillan Cancer Support. He has actively contributed to several funded research grants investigating various topics in health economics, including: value for
money in health care, patient choice and competition, equity, and diffusion of new technologies for the treatment of cancer. His research has been published in
the
Journal of Health Economics, Social Science & Medicine, Health Services Research and Health Affairs
.
Mauro.Laudicella.1@city.ac.ukMauro Laudicella et al., J Cancer Sci Ther 2017, 9:9(Suppl)
DOI: 10.4172/1948-5956-C1-112